Table 4

The baseline characteristics of survivors and non-survivors in patients with severe covid-19 with diabetes

Total (n=48)Survivors (n=9)Non-survivors (n=39) P value*
Number (%)Number (%)Number (%)
Age, mean±SD, years69.4±9.964.7±7.370.5±10.10.112
Sex
 Male33 (68.8)3 (33.3)30 (76.9)0.032
 Female15 (31.3)6 (66.7)9 (23.1)
Diabetes duration, median (IQR), years2 (1 to 5)0.5 (0.5 to 2.5)2 (1 to 5)0.021
Medicine control for diabetes†
 No medication20/34 (58.8)6/9 (66.7)14/25 (56.0)0.266
 Oral medication10/34 (29.4)3/9 (33.3)7/25 (28.0)
 Insulin 4/34 (11.8)0/9 (0.0)4/25 (16.0)
Glycated hemoglobin, %
 <7.017 (35.4)4 (44.4)13 (33.3)0.852
 ≥7.0,<8.016 (33.3)2 (22.2)14 (35.9)
 ≥8.0,<9.011 (22.9)2 (22.2)9 (23.1)
 ≥9.04 (8.3)1 (11.1)3 (7.7)
Symptoms
 Fever43 (89.6)7 (77.8)36 (92.3)0.496
 Cough37 (77.1)3 (33.3)34 (87.2)0.002
 Dyspnea33 (68.8)3 (33.3)30 (76.9)0.032
 Diarrhea10 (20.8)4 (44.4)6 (15.4)0.139
 Nausea2 (4.2)0 (0.0)2 (5.1)1.000
 Anorexia21 (43.8)2 (22.2)19 (48.7)0.284
 Headache5 (10.4)0 (0.0)5 (12.8)0.568
 Fatigue28 (58.3)4 (44.4)24 (61.5)0.574
Comorbidities
 Hypertension24 (50.0)3 (33.3)21 (53.8)0.460
 Cardiovascular disease13 (27.1)2 (22.2)11 (28.2)1.000
 Cerebrovascular disease5 (10.4)0 (0.0)5 (12.8)0.568
 Chronic pulmonary disease4 (8.3)0 (0.0)4 (10.3)1.000
Exposure to disease17 (35.4)6 (66.7)11 (28.2)0.074
ICU patients32 (66.7)0 (0.0)32 (82.1)<0.001
Glucocorticoid treatment39 (81.3)4 (44.4)35 (89.7)0.008
Mechanical ventilation treatment‡39 (81.3)1 (11.1)38 (97.4)<0.001
Length of hospital stay, median (IQR), days10 (6 to 13)14 (11 to 18)9 (6 to 12)0.004
  • *P values indicate differences between survivors and non-survivors. A value of p<0.05 was considered statistically significant.

  • †Data were expressed as n/N (%), where N indicated available total cases.

  • ‡Non-invasive and invasive mechanical ventilation were included. Non-invasive mechanical ventilation included bilevel positive airway pressure ventilation or high-flow nasal cannula oxygen therapy.

  • ICU, intensive care unit.